Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Puma Biotechnology, Inc. (PBYI)

3.09   0.22 (7.67%) 03-31 16:00
Open: 2.9 Pre. Close: 2.87
High: 3.12 Low: 2.84
Volume: 547,404 Market Cap: 149(M)

Technical analysis

as of: 2023-03-31 4:21:10 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.97     One year: 4.89
Support: Support1: 2.13    Support2: 1.77
Resistance: Resistance1: 3.4    Resistance2: 4.19
Pivot: 2.47
Moving Average: MA(5): 2.67     MA(20): 2.55
MA(100): 3.93     MA(250): 3.14
MACD: MACD(12,26): -0.3     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 74.6     %D(3): 57.3
RSI: RSI(14): 54.9
52-week: High: 5.15  Low: 1.6
Average Vol(K): 3-Month: 344 (K)  10-Days: 459 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PBYI ] has closed Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.12 - 3.13 3.13 - 3.14
Low: 2.81 - 2.82 2.82 - 2.84
Close: 3.07 - 3.09 3.09 - 3.11

Company Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Headline News

Fri, 31 Mar 2023
Puma Biotechnology (NASDAQ:PBYI) Lifted to "Buy" at StockNews ... - MarketBeat

Wed, 29 Mar 2023
EXEL: 3 Biotech Stocks Losing Momentum -

Thu, 23 Mar 2023 Lowers Puma Biotechnology (NASDAQ:PBYI) to Hold - MarketBeat

Tue, 14 Mar 2023
Renaissance Technologies LLC reduces its stake in Puma ... - Best Stocks

Tue, 14 Mar 2023
Puma Biotechnology Announces Publication of Phase II Clinical ... - Business Wire

Tue, 07 Mar 2023
Is Puma Biotechnology Inc (PBYI) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 46 (M)
Shares Float 32 (M)
% Held by Insiders 16.9 (%)
% Held by Institutions 60.1 (%)
Shares Short 936 (K)
Shares Short P.Month 1,420 (K)

Stock Financials

EPS -1.52
EPS Est Next Qtl -2.12
EPS Est This Year -8.69
EPS Est Next Year -4.7
Book Value (p.s.) -0.16
Profit Margin (%) 4.5
Operating Margin (%) 12.6
Return on Assets (ttm) 8.1
Return on Equity (ttm) 175
Qtrly Rev. Growth 23.5
Gross Profit (p.s.) 4.51
Sales Per Share 4.69
EBITDA (p.s.) 0.78
Qtrly Earnings Growth 0
Operating Cash Flow -29 (M)
Levered Free Cash Flow -19 (M)

Stock Valuations

PE Ratio -2.04
PEG Ratio 0.2
Price to Book value -20.6
Price to Sales 0.65
Price to Cash Flow -4.95

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.